A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid

Journal of Lipid Research

Volumn 56, Issue 6, 2015, Pages 1222-1233

  Sidhu, Rohini ^a   Jiang, Hui ^a   Farhat, Nicole Y ^b   Carrillo Carrasco, Nuria ^c   Woolery, Myra ^c   Ottinger, Elizabeth ^d   Porter, Forbes D ^b   Schaffer, Jean E ^a   Ory, Daniel S ^a   Jiang, Xuntian ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

2 hydroxypropyl cyclodextrin; Niemann Pick C1 disease; Two dimensional liquid chromatography tandem mass spectrometry; Validation

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CHOLESTEROL DERIVATIVE; NICOTINIC ACID; TERT BUTYL METHYL ETHER; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CHOLESTEROL;

ACCURACY; ARTICLE; ATMOSPHERIC PRESSURE; CALIBRATION; CEREBROSPINAL FLUID; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DERIVATIZATION; HYDROXYCHOLESTEROL BLOOD LEVEL; IONIZATION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; METABOLITE; PHARMACODYNAMICS; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY ANALYSIS; VALIDATION PROCESS; BLOOD; CENTRAL NERVOUS SYSTEM; HUMAN; METABOLISM; NIEMANN PICK DISEASE; TANDEM MASS SPECTROMETRY; UNITED STATES;

BETA-CYCLODEXTRINS; CENTRAL NERVOUS SYSTEM; CHOLESTEROL; CHROMATOGRAPHY, LIQUID; HUMANS; HYDROXYCHOLESTEROLS; NIEMANN-PICK DISEASE, TYPE C; TANDEM MASS SPECTROMETRY; UNITED STATES;

EID: 84937197744     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D058487     Document Type: Article

References (67)

1. Dietschy, J. M., and S. D. Turley. 2001. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12: 105-112.
2. Björkhem, I., and S. Meaney. 2004. Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24: 806-815.
3. Brown, M. S., and J. L. Goldstein. 1997. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 89: 331-340.
4. Lund, E. G., J. M. Guileyardo, and D. W. Russell. 1999. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. USA. 96: 7238-7243.
5. Besga, A., A. Cedazo-Minguez, I. Kareholt, A. Solomon, I. Bjorkhem, B. Winblad, V. Leoni, B. Hooshmand, G. Spulber, A. Gonzalez-Pinto, et al. 2012. Differences in brain cholesterol metabolism and insulin in two subgroups of patients with different CSF biomarkers but similar white matter lesions suggest different pathogenic mechanisms. Neurosci. Lett. 510: 121-126.
6. Bretillon, L., D. Lutjohann, L. Stahle, T. Widhe, L. Bindl, G. Eggertsen, U. Diczfalusy, and I. Bjorkhem. 2000. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J. Lipid Res. 41: 840-845.
7. Bretillon, L., A. Siden, L. O. Wahlund, D. Lutjohann, L. Minthon, M. Crisby, J. Hillert, C. G. Groth, U. Diczfalusy, and I. Bjorkhem. 2000. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci. Lett. 293: 87-90.
8. Karrenbauer, V. D., V. Leoni, E. T. Lim, G. Giovannoni, G. T. Ingle, J. Sastre-Garriga, A. J. Thompson, W. Rashid, G. Davies, D. H. Miller, et al. 2006. Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. Clin. Neurol. Neurosurg. 108: 456-460.
9. Kölsch, H., R. Heun, A. Kerksiek, K. V. Bergmann, W. Maier, and D. Lutjohann. 2004. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci. Lett. 368: 303-308.
10. Leoni, V., C. Mariotti, L. Nanetti, E. Salvatore, F. Squitieri, A. R. Bentivoglio, M. Bandettini di Poggio, S. Piacentini, D. Monza, M. Valenza, et al. 2011. Whole body cholesterol metabolism is impaired in Huntington's disease. Neurosci. Lett. 494: 245-249. [Erratum. 2011. Neurosci. Lett. 498: 171.]
11. Leoni, V., C. Mariotti, S. J. Tabrizi, M. Valenza, E. J. Wild, S. M. Henley, N. Z. Hobbs, M. L. Mandelli, M. Grisoli, I. Bjorkhem, et al. 2008. Plasma 24S-hydroxycholesterol and caudate MRI in premanifest and early Huntington's disease. Brain. 131: 2851-2859.
12. Leoni, V., T. Masterman, U. Diczfalusy, G. De Luca, J. Hillert, and I. Bjorkhem. 2002. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci. Lett. 331: 163-166.
13. Qureischie, H., R. Heun, D. Lutjohann, J. Popp, F. Jessen, C. Ledschbor-Frahnert, H. Thiele, W. Maier, F. Hentschel, P. Kelemen, et al. 2008. CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk. Brain Res. 1232: 1-6.
14. Solomon, A., V. Leoni, M. Kivipelto, A. Besga, A. R. Oksengard, P. Julin, L. Svensson, L. O. Wahlund, N. Andreasen, B. Winblad, et al. 2009. Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease. Neurosci. Lett. 462: 89-93.
15. Teunissen, C. E., C. D. Dijkstra, C. H. Polman, E. L. Hoogervorst, K. von Bergmann, and D. Lutjohann. 2003. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neurosci. Lett. 347: 159-162.
16. Teunissen, C. E., D. Lutjohann, K. von Bergmann, F. Verhey, F. Vreeling, A. Wauters, E. Bosmans, H. Bosma, M. P. van Boxtel, M. Maes, et al. 2003. Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol. Aging. 24: 893-902.
17. Zuliani, G., M. P. Donnorso, C. Bosi, A. Passaro, E. Dalla Nora, A. Zurlo, F. Bonetti, A. F. Mozzi, and C. Cortese. 2011. Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer's disease or vascular dementia: a case-control study. BMC Neurol. 11: 121.
18. Hughes, T. M., C. Rosano, R. W. Evans, and L. H. Kuller. 2013. Brain cholesterol metabolism, oxysterols, and dementia. J. Alzheimers Dis. 33: 891-911.
19. Leoni, V., and C. Caccia. 2013. Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid. Biochem. Pharmacol. 86: 26-36.
20. Dzeletovic, S., O. Breuer, E. Lund, and U. Diczfalusy. 1995. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal. Biochem. 225: 73-80.
21. Kumar, B. S., B. C. Chung, Y. J. Lee, H. J. Yi, B. H. Lee, and B. H. Jung. 2011. Gas chromatography-mass spectrometry-based simultaneous quantitative analytical method for urinary oxysterols and bile acids in rats. Anal. Biochem. 408: 242-252.
22. Matysik, S., H. H. Klunemann, and G. Schmitz. 2012. Gas chromatography-tandem mass spectrometry method for the simultaneous determination of oxysterols, plant sterols, and cholesterol precursors. Clin. Chem. 58: 1557-1564.
23. Burkard, I., K. M. Rentsch, and A. von Eckardstein. 2004. Determination of 24S- and 27-hydroxycholesterol in plasma by high-performance liquid chromatography-mass spectrometry. J. Lipid Res. 45: 776-781.
24. Mazalli, M. R., A. C. Sawaya, M. N. Eberlin, and N. Bragagnolo. 2006. HPLC method for quantification and characterization of cholesterol and its oxidation products in eggs. Lipids. 41: 615-622.
25. DeBarber, A. E., D. Lutjohann, L. Merkens, and R. D. Steiner. 2008. Liquid chromatography-tandem mass spectrometry determination of plasma 24S-hydroxycholesterol with chromatographic separation of 25-hydroxycholesterol. Anal. Biochem. 381: 151-153.
26. Ahonen, L., F. B. Maire, M. Savolainen, J. Kopra, R. J. Vreeken, T. Hankemeier, T. Myohanen, P. Kylli, and R. Kostiainen. 2014. Analysis of oxysterols and vitamin D metabolites in mouse brain and cell line samples by ultra-high-performance liquid chromatography-atmospheric pressure photoionization-mass spectrometry. J. Chromatogr. A. 1364: 214-222.
27. McDonald, J. G., D. D. Smith, A. R. Stiles, and D. W. Russell. 2012. A comprehensive method for extraction and quantitative analysis of sterols and secosteroids from human plasma. J. Lipid Res. 53: 1399-1409.
28. Bandaru, V., and N. J. Haughey. 2014. Quantitative detection of free 24S-hydroxycholesterol, and 27-hydroxycholesterol from human serum. BMC Neurosci. 15: 2.
29. Griffiths, W. J., Y. Wang, G. Alvelius, S. Liu, K. Bodin, and J. Sjovall. 2006. Analysis of oxysterols by electrospray tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 17: 341-362.
30. Griffiths, W. J., M. Hornshaw, G. Woffendin, S. F. Baker, A. Lockhart, S. Heidelberger, M. Gustafsson, J. Sjovall, and Y. Wang. 2008. Discovering oxysterols in plasma: a window on the metabolome. J. Proteome Res. 7: 3602-3612.
31. Karu, K., M. Hornshaw, G. Woffendin, K. Bodin, M. Hamberg, G. Alvelius, J. Sjovall, J. Turton, Y. Wang, and W. J. Griffiths. 2007. Liquid chromatography-mass spectrometry utilizing multi-stage fragmentation for the identification of oxysterols. J. Lipid Res. 48: 976-987.
32. Meljon, A., S. Theofilopoulos, C. H. Shackleton, G. L. Watson, N. B. Javitt, H. J. Knolker, R. Saini, E. Arenas, Y. Wang, and W. J. Griffiths. 2012. Analysis of bioactive oxysterols in newborn mouse brain by LC/MS. J. Lipid Res. 53: 2469-2483.
33. Roberg-Larsen, H., K. Lund, T. Vehus, N. Solberg, C. Vesterdal, D. Misaghian, P. A. Olsen, S. Krauss, S. R. Wilson, and E. Lundanes. 2014. Highly automated nano-LC/MS-based approach for thousand cell-scale quantification of side chain-hydroxylated oxysterols. J. Lipid Res. 55: 1531-1536.
34. Jiang, X., D. S. Ory, and X. Han. 2007. Characterization of oxysterols by electrospray ionization tandem mass spectrometry after one-step derivatization with dimethylglycine. Rapid Commun. Mass Spectrom. 21: 141-152.
35. Honda, A., K. Yamashita, T. Hara, T. Ikegami, T. Miyazaki, M. Shirai, G. Xu, M. Numazawa, and Y. Matsuzaki. 2009. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J. Lipid Res. 50: 350-357.
36. Ayciriex, S., A. Regazzetti, M. Gaudin, E. Prost, D. Dargere, F. Massicot, N. Auzeil, and O. Laprevote. 2012. Development of a novel method for quantification of sterols and oxysterols by UPLC-ESI-HRMS: application to a neuroinflammation rat model. Anal. Bioanal. Chem. 404: 3049-3059.
37. Leoni, V., T. Masterman, F. S. Mousavi, B. Wretlind, L. O. Wahlund, U. Diczfalusy, J. Hillert, and I. Björkhem. 2004. Diagnostic use of cerebral and extracerebral oxysterols. Clin. Chem. Lab. Med. 42: 186-191.
38. Ottinger, E. A., M. L. Kao, N. Carrillo-Carrasco, N. Yanjanin, R. K. Shankar, M. Janssen, M. Brewster, I. Scott, X. Xu, J. Cradock, et al. 2014. Collaborative development of 2-hydroxypropyl-beta-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr. Top. Med. Chem. 14: 330-339.
39. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Veterinary Medicine. 2001. Guidance for Industry: Bioanalytical Method Validations. Accessed April 7, 2015, at http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
40. Scheff, J. D., R. R. Almon, D. C. Dubois, W. J. Jusko, and I. P. Androulakis. 2011. Assessment of pharmacologic area under the curve when baselines are variable. Pharm. Res. 28: 1081-1089.
41. Jemal, M., Z. Ouyang, and Y. Q. Xia. 2010. Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. Biomed. Chromatogr. 24: 2-19.
42. Kadar, E. P., Y. Su, Y. Zhang, J. Tweed, and C. E. Wujcik. 2010. Evaluation of the relationship between a pharmaceutical compound's distribution coefficient, log D and adsorption loss to polypropylene in urine and CSF. Bioanalysis. 2: 755-767.
43. Scifinder. Advanced Chemistry Development (ACD/Labs) software V11.02, © 1994-2014 ACD/Labs. (Accessed April 7, 2015 at http://www.cas.org/products/scifinder.)
44. Ji, A. J., Z. Jiang, Y. Livson, J. A. Davis, J. X. Chu, and N. Weng. 2010. Challenges in urine bioanalytical assays: overcoming nonspecific binding. Bioanalysis. 2: 1573-1586.
45. Viswanathan, C. T., S. Bansal, B. Booth, A. J. DeStefano, M. J. Rose, J. Sailstad, V. P. Shah, J. P. Skelly, P. G. Swann, and R. Weiner. 2007. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24: 1962-1973.
46. Kushnir, M. M., A. L. Rockwood, G. J. Nelson, B. Yue, and F. M. Urry. 2005. Assessing analytical specificity in quantitative analysis using tandem mass spectrometry. Clin. Biochem. 38: 319-327.
47. Kaufmann, A., P. Butcher, K. Maden, M. Widmer, K. Giles, and D. Uria. 2009. Are liquid chromatography/electrospray tandem quadrupole fragmentation ratios unequivocal confirmation criteria? Rapid Commun. Mass Spectrom. 23: 985-998.
48. Vogeser, M., and C. Seger. 2010. Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin. Chem. 56: 1234-1244.
49. Vanier, M. T., and G. Millat. 2003. Niemann-Pick disease type C. Clin. Genet. 64: 269-281.
50. Liu, B., H. Li, J. J. Repa, S. D. Turley, and J. M. Dietschy. 2008. Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J. Lipid Res. 49: 663-669.
51. Liu, B., S. D. Turley, D. K. Burns, A. M. Miller, J. J. Repa, and J. M. Dietschy. 2009. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc. Natl. Acad. Sci. USA. 106: 2377-2382.
52. Davidson, C. D., N. F. Ali, M. C. Micsenyi, G. Stephney, S. Renault, K. Dobrenis, D. S. Ory, M. T. Vanier, and S. U. Walkley. 2009. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE. 4: e6951.
53. Tortelli, B., H. Fujiwara, J. H. Bagel, J. Zhang, R. Sidhu, X. Jiang, N. M. Yanjanin, R. K. Shankar, N. Carillo-Carasco, J. Heiss, et al. 2014. Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1). Hum. Mol. Genet. 23: 6022-6033.
54. Jiang, H., R. Sidhu, H. Fujiwara, M. De Meulder, R. de Vries, Y. Gong, M. Kao, F. D. Porter, N. M. Yanjanin, N. Carillo-Carasco, et al. 2014. Development and validation of sensitive LC-MS/MS assays for quantification of HP-beta-CD in human plasma and CSF. J. Lipid Res. 55: 1537-1548.
55. Lee, J. W., V. Devanarayan, Y. C. Barrett, R. Weiner, J. Allinson, S. Fountain, S. Keller, I. Weinryb, M. Green, L. Duan, et al. 2006. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23: 312-328.
56. Lee, J. W., R. S. Weiner, J. M. Sailstad, R. R. Bowsher, D. W. Knuth, P. J. O'Brien, J. L. Fourcroy, R. Dixit, L. Pandite, R. G. Pietrusko, et al. 2005. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res. 22: 499-511.
57. Jandera, P. 2006. Column selectivity for two-dimensional liquid chromatography. J. Sep. Sci. 29: 1763-1783.
58. Stoll, D. R., X. Li, X. Wang, P. W. Carr, S. E. Porter, and S. C. Rutan. 2007. Fast, comprehensive two-dimensional liquid chromatography. J. Chromatogr. A. 1168: 3-43, discussion 42.
59. François, I., K. Sandra, and P. Sandra. 2009. Comprehensive liquid chromatography: fundamental aspects and practical considerations-a review. Anal. Chim. Acta. 641: 14-31.
60. Na¨gele, E., M. Vollmer, P. Horth, and C. Vad. 2004. 2D-LC/MS techniques for the identification of proteins in highly complex mixtures. Expert Rev. Proteomics. 1: 37-46.
61. Sandra, K., M. Moshir, F. D'Hondt, R. Tuytten, K. Verleysen, K. Kas, I. Francois, and P. Sandra. 2009. Highly efficient peptide separations in proteomics. Part 2: bi- and multidimensional liquid-based separation techniques. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877: 1019-1039.
62. Stoll, D. R. 2010. Recent progress in online, comprehensive two-dimensional high-performance liquid chromatography for non-proteomic applications. Anal. Bioanal. Chem. 397: 979-986.
63. Zhang, K., J. Wang, M. Tsang, L. Wigman, and N. P. Chetwyn. 2013. Two-dimensional HPLC in pharmaceutical analysis. Am. Pharm. Rev. 16: 39-44.
64. Li, M., Z. Zhou, H. Nie, Y. Bai, and H. Liu. 2011. Recent advances of chromatography and mass spectrometry in lipidomics. Anal. Bioanal. Chem. 399: 243-249.
65. Alam, M. S., M. Getz, S. Yi, J. Kurkewich, I. Safeukui, and K. Haldar. 2014. Plasma signature of neurological disease in the monogenetic disorder Niemann-Pick Type C. J. Biol. Chem. 289: 8051-8066.
66. Enzo Life Sciences. Product manual, 24(S)-Hydroxycholesterol ELISA Kit. Accessed April 7, 2015 at http://static.enzolifesciences.com/fileadmin/files/manual/ADI-900-210-insert.pdf.
67. Weibust, R. S. 1973. Inheritance of plasma cholesterol levels in mice. Genetics. 73: 303-312.